2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2023
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized disease
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosisCost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rateAssociations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries
Luo Q, Shi K, Hung P, Wang SY. Associations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries. American Journal Of Hospice And Palliative Medicine® 2021, 38: 626-633. PMID: 33472379, DOI: 10.1177/1049909120988506.Peer-Reviewed Original ResearchConceptsAggressive EOL careLow health literacyEOL careHealth literacyMedicare beneficiariesHospital deathCare intensityHigher oddsEOL care intensityLife care intensityPatient-provider communicationProportion of decedentsMonths of lifeDays of lifeHospice enrollmentHL scoreMultivariable analysisHospice useCare measuresRetrospective analysisLife careMedicare feeService decedentsDecedentsCareTrend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016
Yang SC, Gross C, Wang JD, Wang SY. Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016. Journal Of General Internal Medicine 2021, 36: 3589-3591. PMID: 33469753, PMCID: PMC8606484, DOI: 10.1007/s11606-020-06586-4.Peer-Reviewed Original ResearchEnd-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis
Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Supportive Care In Cancer 2021, 29: 3921-3932. PMID: 33389087, DOI: 10.1007/s00520-020-05964-2.Peer-Reviewed Original ResearchConceptsCancer-directed therapySymptom management servicesLung cancerMedicare beneficiariesCare contentYounger ageEarlier hospice enrollmentLife care patternsLung cancer decedentsPercentage of patientsClaims-based analysisMethodsThis retrospective studyMost Medicare beneficiariesNonhospice settingsCancer decedentsUsual careHospice enrollmentSymptom managementRetrospective studyMedicare databaseSkilled nursingHigh comorbidityCare intensityMedicare claimsMultinomial logistic regression
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsTreatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchRacial and Ethnic Disparities in Population-Level Covid-19 Mortality
Gross CP, Essien UR, Pasha S, Gross JR, Wang SY, Nunez-Smith M. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. Journal Of General Internal Medicine 2020, 35: 3097-3099. PMID: 32754782, PMCID: PMC7402388, DOI: 10.1007/s11606-020-06081-w.Peer-Reviewed Original ResearchTrends in Provision of Palliative Radiotherapy and Chemotherapy Among Hospices in the United States, 2011-2018
Hsu SH, Wang SY. Trends in Provision of Palliative Radiotherapy and Chemotherapy Among Hospices in the United States, 2011-2018. JAMA Oncology 2020, 6: 1106-1108. PMID: 32352492, PMCID: PMC7193522, DOI: 10.1001/jamaoncol.2020.0923.Peer-Reviewed Original ResearchGeographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatmentAssociations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration
Hung P, Hsu SH, Wang SY. Associations Between End-of-Life Expenditures and Hospice Stay Length Vary by Clinical Condition and Expenditure Duration. Value In Health 2020, 23: 697-704. PMID: 32540226, DOI: 10.1016/j.jval.2020.01.021.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary diseaseCongestive heart failureEOL expendituresHospice staysEnd Results-Medicare dataLonger hospice staysObstructive pulmonary diseaseMonths of lifeDays of lifeDistinct disease trajectoriesPatient disease groupsCancer decedentsDifferential associationsHeart failureAggressive endPulmonary diseaseHospice lengthMedical covariatesCancer patientsHospice useDisease groupClinical conditionsLife careDisease trajectoriesPatientsChanges in community mental health services availability and suicide mortality in the US: a retrospective study
Hung P, Busch SH, Shih YW, McGregor AJ, Wang S. Changes in community mental health services availability and suicide mortality in the US: a retrospective study. BMC Psychiatry 2020, 20: 188. PMID: 32334552, PMCID: PMC7183673, DOI: 10.1186/s12888-020-02607-y.Peer-Reviewed Original ResearchConceptsSuicide mortalityNational Mental Health Services SurveySuicide deathsMental health service availabilityHealth service availabilityMental health servicesMental health careHealth Services SurveySuicide prevention effortsMethodsRetrospective analysisRetrospective studyOutpatient settingHealth servicesDisease controlResultsFrom 2014Same time periodEpidemiologic researchCMHCsPrevention effortsMortalityHealth careServices SurveySuicide ratesAssociationDeathSevere functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer
Presley CJ, Canavan M, Wang SY, Feder SL, Kapo J, Saphire ML, Sheinfeld E, Kent EE, Davidoff AJ. Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer. Journal Of Geriatric Oncology 2020, 11: 960-968. PMID: 32169548, PMCID: PMC7346676, DOI: 10.1016/j.jgo.2020.02.006.Peer-Reviewed Original ResearchConceptsSevere functional limitationsCo-occurring symptomsFunctional limitationsOlder adultsPrescription medicationsEmotional distressOlder adult Medicare beneficiariesAdult Medicare beneficiariesPrescription claims dataStage IV diseaseSupportive care needsMultivariable logistic regressionPrescription medication useMedicare Part D enrollmentPart D enrollmentCertain cancer typesMedication useLung cancerClaims dataPainMedicare beneficiariesCare needsFunctional independenceParticipant characteristicsCancerGlobal reach of ageism on older persons’ health: A systematic review
Chang ES, Kannoth S, Levy S, Wang SY, Lee JE, Levy BR. Global reach of ageism on older persons’ health: A systematic review. PLOS ONE 2020, 15: e0220857. PMID: 31940338, PMCID: PMC6961830, DOI: 10.1371/journal.pone.0220857.Peer-Reviewed Original ResearchConceptsSystematic reviewOlder personsHealth outcomesOlder persons' healthPrevious systematic reviewWorse health outcomesComprehensive systematic reviewAdverse health effectsRace/ethnicityStudy protocolStudy qualityEvidence of ageismGreater prevalenceHealth consequencesLiterature searchSystematic searchHealth effectsHealth domainsStandardized toolsPerson's healthPrevalenceHealthFull reviewOutcomesSignificant findings
2019
“Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer
Wang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer. Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerRisk calculatorLocal recurrenceBreast cancerOlder womenTumor characteristicsBreast cancer-specific outcomesReceipt of radiotherapyCancer-specific outcomesEarly breast cancerIndividual patient's riskBenefits of radiotherapyAdvisory CommitteeLife expectancyOnline risk calculatorLong-term survivalShared decision makingBenefit of RTOlder adult womenRadiotherapy statusCause mortalityOverall survivalRecurrence reductionFunctional statusPatient riskIncome disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups
Killelea BK, Herrin J, Soulos PR, Pollack CE, Forman HP, Yu J, Xu X, Tannenbaum S, Wang SY, Gross CP. Income disparities in needle biopsy patients prior to breast cancer surgery across physician peer groups. Breast Cancer 2019, 27: 381-388. PMID: 31792804, PMCID: PMC7512133, DOI: 10.1007/s12282-019-01028-4.Peer-Reviewed Original ResearchConceptsPhysician peer groupsLow-income patientsNeedle biopsyOdds ratioHigh-income patientsBreast cancer surgeryMethodsThe SurveillanceCancer surgeryIncome patientsMedicare databaseBiopsy patientsMedicare beneficiariesPatientsBiopsyLow incomeGroupDisparitiesReceiptEnd resultHigher incomeSurgeryPeer groupEpidemiologyFurther workGroup-level effectsA Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. Value In Health 2019, 22: 1102-1110. PMID: 31563252, PMCID: PMC7343670, DOI: 10.1016/j.jval.2019.05.004.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerObservational studyBreast cancerLow-risk early-stage breast cancerHormone receptor-positive early-stage breast cancerPredictive valueLow-risk womenProspective observational studyHigh-risk womenRetrospective observational studyBreast cancer managementQuality-adjusted life yearsCost-effectiveness findingsTraditional risk predictionAdjuvant chemotherapyChemotherapy useAlternative study designsOncotype DXCancer managementClinical utilityCurrent evidenceInsufficient evidenceLife yearsRoutine useStudy design